



President
Caralee Schaefer, PhD
4DMT
president@inflammationresearch.org

Vice President
Alison O'Mahony, PhD
Recursion Pharmaceuticals
vicepresident@inflammationresearch.org

Treasurer
Dirk Smith, MSc.
Cascadia Drug Development Grp.
treasurer@inflammationresearch.org

Secretary
Howard Kartstein
Certis Oncology
secretary@inflammationresearch.org

Board Members:

Albert Sek PhD
Merck
albert.sek@merck.com

Caitlin Parello, PhD
Biomodels
cparello@biomodels.com

Fiona Kuo, PhD
RAPT Therapeutics
fkuo@rapt.com

Heather Jones, RN
AbbVie
heather.jones@abbvie.com

Lisa Schopf, PhD
Pfizer
lisa.schopf@pfizer.com

Liwu Li, PhD
Immediate Past President
Virginia Polytechnic Institute
lwli@vt.edu

Siquan Sun, PhD
Janssen R & D
ssun1@its.jnj.com

Wendy Peters, PhD
Gilead
wendy_peters24@hotmail.com

Xiao-Feng Yang, MD, PhD, FAHA
Temple U. School of Medicine
xiao-feng.yang@temple.edu

EMERGING THERAPEUTIC PLATFORMS FOR THE TREATMENT OF AUTOIMMUNE & INFLAMMATORY DISEASE

Monday November 4 2024- GSK Waltham MA – Innovation Center

Organizers - Maud Deruaz, Heidi Feldser and Joel Tocker

8:00 – 8:30 – Registration and light breakfast

8:30 – 8:40 – Introduction

**8:40 – 9:15 (Keynote)– Vini Mani, Flagship Pioneering & ProFound Therapeutics
Innovating bio-platforms to create first-in-class medicines**

**9:15 – 9:50 – David Ciccone, Nimbus Therapeutics
HPGD Inhibition is a Potent Mechanism to Dampen the Autoimmune
Response and Restore Intestinal Integrity in Inflammatory Bowel Disease**

**9:50 – 10:25 – Caroline Sokol, MGB/HMS
A neuroimmune rheostat driving itch and allergic disease**

10:25 – 10:45 – BREAK

**10:45 – 11:20 – Chloe Jones, GSK
Leveraging encoded technologies for novel binder discovery**

**11:20 – 11:55 – Jay Rothstein, Lifordi
Targeted delivery of small molecules and nucleic acids to immune cells using ADCs**

11:55 – 1:00 – BOX LUNCH

**1:00 – 1:35 – Ivan Mascanfroni, Seismic Therapeutic
The promise of machine learning: using Seismic's IMPACT platform to design IgG
cleaving enzymes for chronic treatment of autoimmune diseases**

**1:35 – 2:10 – Gabby Dower, Mediar Therapeutic
Anti-WISP1 (MTX-463) as a novel potential therapy for idiopathic pulmonary fibrosis**

2:10 – 2:30 – BREAK

**2:30 – 3:05 – Zaida Ramirez Ortiz, University of Massachusetts Medical School
Exploring the role of Scarf1 in the pathogenesis of autoimmunity**

**3:05 – 3:40 – Nan Zheng, Nocion Therapeutics
Championing a novel approach to atopic dermatitis therapy through silencing
nociceptors with charged sodium channel blockers**

3:40 – 3:55 – Closing remarks

4:00 – 5:00 – Post meeting reception & networking